Dyne Therapeutics (NASDAQ:DYN) CFO Sells $48,113.94 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CFO Erick Lucera sold 2,362 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares in the company, valued at $2,476,238.31. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Erick Lucera also recently made the following trade(s):

• On Wednesday, May 13th, Erick Lucera sold 1,448 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.36, for a total value of $26,585.28.

Dyne Therapeutics Price Performance

Shares of DYN opened at $20.94 on Monday. The business has a 50-day moving average of $18.45 and a 200-day moving average of $18.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -6.50 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the firm earned ($1.05) earnings per share. As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday. They set a “buy” rating on the stock. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Chardan Capital reissued a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Sanford C. Bernstein boosted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the first quarter worth $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC boosted its position in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after purchasing an additional 1,440 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.